NASDAQ:SNOA

Sonoma Pharmaceuticals Q1 2027 Earnings Results & Report

Sonoma Pharmaceuticals logo
$0.72 -0.09 (-10.83%)
Closing price 04:00 PM Eastern
Extended Trading
$0.72 -0.01 (-0.69%)
As of 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Sonoma Pharmaceuticals beat analyst expectations on both earnings and revenue in its Q1 2027 results, released August 6, 2026. The company reported EPS of $0.02 versus the -$0.30 consensus estimate, while revenue of $6.41 million topped the $4.99 million estimate by $1.42 million.

Earnings Announcement Details

Quarter
Q1 2027
Report Date
Time
Before Market Opens

Sonoma Pharmaceuticals EPS Results

Actual EPS
$0.02
Consensus EPS
-$0.30
Beat/Miss
Beat by +$0.32
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 8 quarters

Sonoma Pharmaceuticals Revenue Results

Actual Revenue
$6.41 million
Expected Revenue
$4.99 million
Beat/Miss
Beat by +$1.42 million
YoY Revenue Growth
N/A

Sonoma Pharmaceuticals Q1 2027 Earnings FAQ

Sonoma Pharmaceuticals (NASDAQ:SNOA) reported earnings of $0.02 per share for Q1 2027, beating the consensus estimate of -$0.30. The report was announced on Thursday, August 6, 2026.

Sonoma Pharmaceuticals reported revenue of $6.41 million for Q1 2027, against a consensus estimate of $4.99 million.

Sonoma Pharmaceuticals Earnings Headlines

Every Starlink dish pays this stock
There's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now he's filed to launch 1,000,000 AI satellites, a move Dylan believes could mean a 100X bigger royalty bill starting December 8th. This free pick names the public company collecting on every unit.tc pixel
See More Sonoma Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sonoma Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sonoma Pharmaceuticals and other key companies, straight to your email.

About Sonoma Pharmaceuticals

Sonoma Pharmaceuticals (NASDAQ:SNOA) develops and markets products based on its stabilized hypochlorous acid technology for human and animal health. Its product portfolio includes solutions and gels for wound care, skin conditions, eye care and other hygiene applications.

The company’s offerings include Microcyn-branded products, which are used in areas such as wound management and dermatology, as well as products for veterinary care. Sonoma sells its products through commercial partners and distributors in the United States and international markets.

The company was formerly known as Oculus Innovative Sciences and adopted the Sonoma Pharmaceuticals name in 2016. Its business has since focused on developing and commercializing hypochlorous acid-based products for healthcare and related markets.

View Sonoma Pharmaceuticals Profile